2Rabe KF,Hurd S,Anzueto A,et al.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmoary disease:GOLD executive summary[J].Am J Respir Crit Care Med,2007,176(6):532.
3Celli BR,MacNee W.Standards for the diagnosis and treatment of COPD[J].Eur Respir J,2004,23(4):932.
4American Thoracic Society.Standards for the diagnosis and case of patients with chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,1995,152(1):78.
5O′Donnell D,Lam M,Webb K.Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,1999,160(3):542.
6Van Noord J,Aumann J,Jasnseens E,et al.Comparison of tiotropium qd,formoterol bid and both combined qd in patients with COPD[J].Eur Respir J,2005,26(2):214.
7Barnes PJ,Ito K,Adcock IM.Corticosteroid resistance in chronic obstructive pulmonary disease:inactivation of histone deacetylase[J].Lancet,2004,363(3):731.
8Friedman M,Serby C,Menjoge S,et al.Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD[J].Chest,1999,115(3):635.
2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
